vs
Idexx Laboratories（IDXX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Idexx Laboratories的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Idexx Laboratories净利率更高（22.8% vs 12.7%，领先10.0%），Idexx Laboratories同比增速更快（14.3% vs 5.9%），Idexx Laboratories自由现金流更多（$326.3M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 6.4%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
IDXX vs RVTY — 直观对比
营收规模更大
IDXX
是对方的1.4倍
$772.1M
营收增速更快
IDXX
高出8.4%
5.9%
净利率更高
IDXX
高出10.0%
12.7%
自由现金流更多
IDXX
多$164.5M
$161.8M
两年增速更快
RVTY
近两年复合增速
6.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $248.2M | $98.4M |
| 毛利率 | 60.3% | — |
| 营业利润率 | 28.9% | 14.5% |
| 净利率 | 22.8% | 12.7% |
| 营收同比 | 14.3% | 5.9% |
| 净利润同比 | 14.8% | 3.9% |
| 每股收益（稀释后） | $3.09 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $998.4M | $664.8M | ||
| Q4 24 | $954.3M | $729.4M | ||
| Q3 24 | $975.5M | $684.0M | ||
| Q2 24 | $1.0B | $691.7M | ||
| Q1 24 | $964.1M | $649.9M |
净利润IDXXRVTY
| Q4 25 | $248.2M | $98.4M | ||
| Q3 25 | $274.6M | $46.7M | ||
| Q2 25 | $294.0M | $53.9M | ||
| Q1 25 | $242.7M | $42.2M | ||
| Q4 24 | $216.1M | $94.6M | ||
| Q3 24 | $232.8M | $94.4M | ||
| Q2 24 | $203.3M | $55.4M | ||
| Q1 24 | $235.6M | $26.0M |
毛利率IDXXRVTY
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | 53.6% | ||
| Q2 25 | 62.6% | 54.5% | ||
| Q1 25 | 62.4% | 56.5% | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | 56.3% | ||
| Q2 24 | 61.7% | 55.7% | ||
| Q1 24 | 61.5% | 54.6% |
营业利润率IDXXRVTY
| Q4 25 | 28.9% | 14.5% | ||
| Q3 25 | 32.1% | 11.7% | ||
| Q2 25 | 33.6% | 12.6% | ||
| Q1 25 | 31.7% | 10.9% | ||
| Q4 24 | 27.4% | 16.3% | ||
| Q3 24 | 31.2% | 14.3% | ||
| Q2 24 | 26.3% | 12.4% | ||
| Q1 24 | 31.0% | 6.8% |
净利率IDXXRVTY
| Q4 25 | 22.8% | 12.7% | ||
| Q3 25 | 24.8% | 6.7% | ||
| Q2 25 | 26.5% | 7.5% | ||
| Q1 25 | 24.3% | 6.4% | ||
| Q4 24 | 22.7% | 13.0% | ||
| Q3 24 | 23.9% | 13.8% | ||
| Q2 24 | 20.3% | 8.0% | ||
| Q1 24 | 24.4% | 4.0% |
每股收益（稀释后）IDXXRVTY
| Q4 25 | $3.09 | $0.86 | ||
| Q3 25 | $3.40 | $0.40 | ||
| Q2 25 | $3.63 | $0.46 | ||
| Q1 25 | $2.96 | $0.35 | ||
| Q4 24 | $2.62 | $0.77 | ||
| Q3 24 | $2.80 | $0.77 | ||
| Q2 24 | $2.44 | $0.45 | ||
| Q1 24 | $2.81 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $919.9M |
| 总债务越低越好 | $450.0M | — |
| 股东权益账面价值 | $1.6B | $7.3B |
| 总资产 | $3.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资IDXXRVTY
| Q4 25 | $180.1M | $919.9M | ||
| Q3 25 | $208.2M | $931.4M | ||
| Q2 25 | $164.6M | $991.8M | ||
| Q1 25 | $164.0M | $1.1B | ||
| Q4 24 | $288.3M | $1.2B | ||
| Q3 24 | $308.6M | $1.2B | ||
| Q2 24 | $401.6M | $2.0B | ||
| Q1 24 | $397.4M | $1.7B |
总债务IDXXRVTY
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IDXXRVTY
| Q4 25 | $1.6B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.5B | $7.6B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
总资产IDXXRVTY
| Q4 25 | $3.4B | $12.2B | ||
| Q3 25 | $3.4B | $12.1B | ||
| Q2 25 | $3.3B | $12.4B | ||
| Q1 25 | $3.2B | $12.4B | ||
| Q4 24 | $3.3B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.4B | $13.4B | ||
| Q1 24 | $3.4B | $13.4B |
负债/权益比IDXXRVTY
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 29.9% | 21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.43× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $509.4M |
8季度趋势，按日历期对齐
经营现金流IDXXRVTY
| Q4 25 | $355.8M | $182.0M | ||
| Q3 25 | $402.3M | $138.5M | ||
| Q2 25 | $185.7M | $134.3M | ||
| Q1 25 | $238.0M | $128.2M | ||
| Q4 24 | $262.0M | $174.2M | ||
| Q3 24 | $220.1M | $147.9M | ||
| Q2 24 | $248.3M | $158.6M | ||
| Q1 24 | $198.6M | $147.6M |
自由现金流IDXXRVTY
| Q4 25 | $326.3M | $161.8M | ||
| Q3 25 | $371.2M | $120.0M | ||
| Q2 25 | $151.6M | $115.5M | ||
| Q1 25 | $207.9M | $112.2M | ||
| Q4 24 | $232.8M | $149.8M | ||
| Q3 24 | $192.0M | $125.6M | ||
| Q2 24 | $215.0M | $136.6M | ||
| Q1 24 | $168.3M | $129.7M |
自由现金流率IDXXRVTY
| Q4 25 | 29.9% | 21.0% | ||
| Q3 25 | 33.6% | 17.2% | ||
| Q2 25 | 13.7% | 16.0% | ||
| Q1 25 | 20.8% | 16.9% | ||
| Q4 24 | 24.4% | 20.5% | ||
| Q3 24 | 19.7% | 18.4% | ||
| Q2 24 | 21.4% | 19.7% | ||
| Q1 24 | 17.5% | 20.0% |
资本支出强度IDXXRVTY
| Q4 25 | 2.7% | 2.6% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 3.0% | 2.4% | ||
| Q4 24 | 3.1% | 3.4% | ||
| Q3 24 | 2.9% | 3.3% | ||
| Q2 24 | 3.3% | 3.2% | ||
| Q1 24 | 3.1% | 2.7% |
现金转化率IDXXRVTY
| Q4 25 | 1.43× | 1.85× | ||
| Q3 25 | 1.47× | 2.97× | ||
| Q2 25 | 0.63× | 2.49× | ||
| Q1 25 | 0.98× | 3.03× | ||
| Q4 24 | 1.21× | 1.84× | ||
| Q3 24 | 0.95× | 1.57× | ||
| Q2 24 | 1.22× | 2.87× | ||
| Q1 24 | 0.84× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
